Drugs / CAP256V2LS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07810062 | Aug 2023 → Jun 2024 | — | Centre for Infectious Disease Research in Zambia | Completed | No outcome recorded |
| Phase 2 | NCT05281510 | Jun 2022 → Jan 2025 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-03-12 | Gilead Sciences | Results Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option gilead.com ↗
Results presented at CROI showed the treatment combination was generally well-tolerated with no treatment-related serious adverse events (TEAEs) reported. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-03-12 | Gilead Sciences | Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option gilead.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAP256V2LS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07810062 ↗ |
| Modality | Monoclonal antibody | “CAP256V2LS and VRC07-523LS monoclonal antibodies” NCT07810062 ↗ |
| Route | Intravenous | “Administered intravenously” NCT05281510 ↗ |